Alto Neuroscience (ANRO) Corporate presentation summary

Mission and strategic approach

• Aims to redefine psychiatry by developing personalized, neurobiology-driven medicines for mental health disorders.

• Focuses on precision medicine using biomarkers to identify responsive patient populations and reduce trial-and-error treatments.

• Utilizes a biomarker platform to segment patients and guide drug development, improving outcomes and reducing development risk.

Portfolio and clinical pipeline

• Over 900 patients dosed across studies, with four late-stage data readouts expected in the next three years.

• Lead programs include ALTO-207 for treatment-resistant depression (TRD), ALTO-300 for major depressive disorder (MDD), and ALTO-100 for bipolar depression, all leveraging biomarker-guided approaches.

• Additional programs target cognitive disorders and Parkinson’s disease, with multiple independent candidates in development.

ALTO-207 for TRD

• Combines a D3/D2 agonist (pramipexole) with a 5-HT3 antagonist (ondansetron) to enhance antidepressant effects and reduce dose-limiting side effects.

• Demonstrated robust antidepressant efficacy and improved tolerability, enabling higher and faster dosing compared to pramipexole alone.

• Ongoing Phase 2b trial with topline results expected in 2H 2027; Phase 3 initiation planned for early 2027.

• Strong patent protection and commercial strategies mitigate risk of generic substitution.